Results 251 to 260 of about 61,255 (306)
Cardiotoxicity in patients with acute myeloid leukaemia following anthracycline-containing chemotherapy: A population-based matched cohort study. [PDF]
Br J HaematolJensen RH +10 more
europepmc +1 more source
Incidental apical left ventricular mural thrombus late after myocardial infarction with chronic myeloid leukaemia detected by cardiac magnetic resonance: a case report. [PDF]
Eur Heart J Case RepNguyen QM +4 more
europepmc +1 more source
Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia. [PDF]
EJHaemMannis GN +17 more
europepmc +1 more source
The emerging functions and clinical implications of circRNAs in acute myeloid leukaemia. [PDF]
Cancer Cell IntLiu S +8 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The Lancet, 2023
Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The past decade has witnessed an increasingly improved scientific understanding of the underlying biology of acute myeloid leukaemia, leading to enhanced prognostication tools and refined risk assessments, and most especially incorporating measurable residual disease ...
Courtney D, DiNardo +3 more
openaire +2 more sources
Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The past decade has witnessed an increasingly improved scientific understanding of the underlying biology of acute myeloid leukaemia, leading to enhanced prognostication tools and refined risk assessments, and most especially incorporating measurable residual disease ...
Courtney D, DiNardo +3 more
openaire +2 more sources
The Lancet, 2021
Tyrosine-kinase inhibitors have changed the natural history of chronic myeloid leukaemia in such a way that patients with adequate access to these agents, who are properly managed, and who respond well to this treatment can expect a near-normal life expectancy.
Jorge, Cortes +2 more
openaire +3 more sources
Tyrosine-kinase inhibitors have changed the natural history of chronic myeloid leukaemia in such a way that patients with adequate access to these agents, who are properly managed, and who respond well to this treatment can expect a near-normal life expectancy.
Jorge, Cortes +2 more
openaire +3 more sources
2020
Abstract Acute myeloid leukaemia (AML) is the second most frequent type of leukaemia in children, and is cured nowadays in about 80% of patients in settings with essentially unlimited resources. This chapter discusses the aetiology and epidemiology of this interesting disease, and its typical clinical presentation, diagnostics, and ...
Gertjan Kaspers, Dirk Reinhardt
+4 more sources
Abstract Acute myeloid leukaemia (AML) is the second most frequent type of leukaemia in children, and is cured nowadays in about 80% of patients in settings with essentially unlimited resources. This chapter discusses the aetiology and epidemiology of this interesting disease, and its typical clinical presentation, diagnostics, and ...
Gertjan Kaspers, Dirk Reinhardt
+4 more sources
The Lancet, 2006
Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haemopoietic progenitor cells and the most common malignant myeloid disorder in adults. The median age at presentation for patients with AML is 70 years. In the past few years, research in molecular biology has been instrumental in deciphering the pathogenesis of the disease.
Elihu, Estey, Hartmut, Döhner
openaire +3 more sources
Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haemopoietic progenitor cells and the most common malignant myeloid disorder in adults. The median age at presentation for patients with AML is 70 years. In the past few years, research in molecular biology has been instrumental in deciphering the pathogenesis of the disease.
Elihu, Estey, Hartmut, Döhner
openaire +3 more sources